135 related articles for article (PubMed ID: 31825664)
21. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
23. Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC.
Badellino S; Levis M; Cuffini EM; Cerrato M; Orlandi E; Chiovatero I; Aprile A; Gastino A; Cavallin C; Iorio GC; Parise R; Mantovani C; Ricardi U
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326616
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.
Franceschini D; Teriaca MA; Di Cristina L; Vernier V; Lo Faro L; Franzese C; Comito T; Clerici E; Bellu L; Dominici L; Spoto R; Massaro M; Navarria P; Scorsetti M
Br J Radiol; 2023 Mar; 96(1144):20220771. PubMed ID: 36809197
[TBL] [Abstract][Full Text] [Related]
25. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.
Pollom EL; Alagappan M; von Eyben R; Kunz PL; Fisher GA; Ford JA; Poultsides GA; Visser BC; Norton JA; Kamaya A; Cox VL; Columbo LA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):918-25. PubMed ID: 25585785
[TBL] [Abstract][Full Text] [Related]
26. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.
Pasqualetti F; Panichi M; Sainato A; Matteucci F; Galli L; Cocuzza P; Ferrazza P; Coraggio G; Pasqualetti G; Derosa L; Sollini M; Mannelli L; Ortori S; Monzani F; Ricci S; Greco C; Fabrini MG; Erba PA
Radiat Oncol; 2016 Jan; 11():9. PubMed ID: 26796633
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
Franzese C; Di Brina L; D'Agostino G; Franceschini D; Comito T; De Rose F; Tozzi A; Navarria P; Scorsetti M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2469-2479. PubMed ID: 31444549
[TBL] [Abstract][Full Text] [Related]
29. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: A retrospective experience.
Francolini G; Desideri I; Detti B; Di Cataldo V; Masi L; Caramia G; Visani L; Terziani F; Muntoni C; Lo Russo M; Loi M; Livi L
Cancer Treat Res Commun; 2019; 19():100124. PubMed ID: 30851645
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a monoinstitutional study.
Facondo G; Vullo G; Valeriani M; Ascolese AM; De Sanctis V; Osti MF
Cancer Treat Res Commun; 2021; 29():100481. PubMed ID: 34700142
[TBL] [Abstract][Full Text] [Related]
33. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease.
Rieber J; Abbassi-Senger N; Adebahr S; Andratschke N; Blanck O; Duma M; Eble MJ; Ernst I; Flentje M; Gerum S; Hass P; Henkenberens C; Hildebrandt G; Imhoff D; Kahl H; Klass ND; Krempien R; Lohaus F; Lohr F; Petersen C; Schrade E; Streblow J; Uhlmann L; Wittig A; Sterzing F; Guckenberger M
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):511-520. PubMed ID: 27843031
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma.
Loi M; Duijm M; Baker S; Rossi L; Grunhagen D; Verhoef C; Nuyttens J
Radiol Med; 2018 Nov; 123(11):871-878. PubMed ID: 29923086
[TBL] [Abstract][Full Text] [Related]
35. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial.
Trovo M; Furlan C; Polesel J; Fiorica F; Arcangeli S; Giaj-Levra N; Alongi F; Del Conte A; Militello L; Muraro E; Martorelli D; Spazzapan S; Berretta M
Radiother Oncol; 2018 Jan; 126(1):177-180. PubMed ID: 28943046
[TBL] [Abstract][Full Text] [Related]
36. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
[TBL] [Abstract][Full Text] [Related]
37. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
38. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
39. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT.
Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT
Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients.
Kim CH; Ling DC; Wegner RE; Flickinger JC; Heron DE; Zeh H; Moser AJ; Burton SA
Radiat Oncol; 2013 Oct; 8():240. PubMed ID: 24131503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
